The Filing Desk

BridgeBio Pharma

BBIO · Nasdaq · Health Care · Financials, fiscal 2017 to 2025

BBIO · Last close · November 19, 2026
$78.18
Value BridgeBio Pharma yourself

BridgeBio Pharma's revenue rose 126.3% to $502 million in fiscal 2025. Its operating margin was −104.2%, up from −267.2% a year earlier. Free cash flow was −$447 million. It paid out $48 million in dividends and buybacks. The diluted share count rose 2.9%.

BridgeBio Pharma, Inc. Latest fiscal year ended December 31, 2025 10-K filed February 24, 2026 · 0001743881-26-000009 Updated
Revenue
$502M
126.3%
Operating margin
−104.2%
163.0 pts
Net income
−$733M
 
Free cash flow
−$447M
 
Return on equity
—
 
Market cap
$15.3B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What BridgeBio Pharma does

BridgeBio Pharma is a drug company that develops medicines for genetic diseases. It says more than 8,500 patients have been treated with its approved medicines, and the FDA has approved three of its products. Its largest product is acoramidis, approved in November 2024 for a heart condition called transthyretin amyloid cardiomyopathy and sold in the United States as Attruby.

Outside the United States acoramidis is sold as Beyonttra, through partners such as Bayer in Europe and Alexion in Japan, and directly by BridgeBio in some other markets. It earns money from its product sales and works with partners abroad. It runs a decentralized "hub and spoke" model, with a separate team for each program in its portfolio.

It plans to seek approval for several late-stage candidates, including treatments for achondroplasia, limb-girdle muscular dystrophy type 2I/R9, and autosomal dominant hypocalcemia type 1, which have all released positive Phase 3 data.

Its biggest risks, as it describes them

  • Its dependence on the commercial success of Attruby and Beyonttra.
  • Delays or setbacks in clinical trials, including difficulty enrolling patients.
  • Efforts to lower drug prices, such as reference pricing and most-favored-nation models.
  • Penalties if it fails to follow healthcare laws and government drug pricing program rules.
  • Smaller markets for its drug candidates than it expects.
From BridgeBio Pharma's annual report on Form 10-K, filed February 24, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

BridgeBio Pharma lost money in fiscal 2025: a net loss of $733 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments788428376681588
Debt incl. finance leases4324314464372,007
Net debt (negative means net cash)−355370−2441,420
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−12.3x−6.4x−7.5x−6.5x−9.9x
Current ratio6.6x4.5x3.3x4.7x2.8x
Quick ratio6.6x4.5x3.3x4.7x2.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project BridgeBio Pharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought BridgeBio Pharma shares on the open market, and 7 insiders sold $86.2 million, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Sep 17, 2026Neil KumarChief Executive Officer, DirectorSold plan10,000$69.08$690,816Form 4
Aug 19, 2026Neil KumarChief Executive Officer, DirectorSold plan10,000$84.03$840,273Form 4
Aug 18, 2026Neil KumarChief Executive Officer, DirectorSold plan34,980$82.53$2.9 millionForm 4
Jul 30, 2026Maricel ApuliChief Accounting OfficerSold plan2,000$80.06$160,120Form 4
Jul 9, 2026Jennifer E. CookDirectorSold plan148,589$88.54$13.2 millionForm 4
Jul 9, 2026Andrea EllisDirectorSold plan17,167$84.00$1.4 millionForm 4
Jun 24, 2026Jennifer E. CookDirectorSold plan37,167$70.00$2.6 millionForm 4
Jun 23, 2026Hannah ValantineDirectorSold plan2,196$68.57$150,580Form 4
Jun 22, 2026Hannah ValantineDirectorSold plan2,808$68.00$190,944Form 4
Jun 15, 2026Jennifer E. CookDirectorSold plan90,240$66.63$6.0 millionForm 4
Jun 5, 2026Neil KumarChief Executive Officer, DirectorSold plan40,000$67.88$2.7 millionForm 4
Jun 4, 2026Neil KumarChief Executive Officer, DirectorSold plan40,000$67.46$2.7 millionForm 4
The latest 12 of 39 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score1 of 96 of 93 of 9
Rule of 40−5,774.6%2,050.2%37.2%
Altman Z''−19.49−11.92−14.22
Accruals ratio−21.5%−3.1%−30.9%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsFailPassPass
F-score1 of 96 of 93 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put BridgeBio Pharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
BridgeBio PharmaFY25126.3%−104.2%−89.0%——3
Travere TherapeuticsFY25110.5%−12.8%———7Compare
Mirum PharmaceuticalsFY2554.7%−4.2%10.5%−7.1%−34.9x5Compare
Zai LabFY2515.3%−49.9%−34.5%———Compare
HUTCHMED (China)FY25−13.0%−7.1%−14.4%——4Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue——41870789222502
Revenue growth———−79.7%745.1%11.4%−88.0%2,285.3%126.3%
Gross profit————67747218481
Research and development31140210337451400456506452
Operating income−44−184−266−474−577−512−607−593−523
Net income−44−170−289−506−586−485−653−543−733
Diluted EPS (US$)−1.00−2.12−2.48−3.80−3.90−3.26−3.95−2.88−3.78
Diluted shares (millions)3162105118144148163186192
Cash flow
Cash from operations−40−137−254−400−498−420−528−521−446
Capital expenditure0238135111
Free cash flow−41−139−256−407−511−424−529−522−447
Dividends paid101000000
Share buybacks0007520000048
Acquisitions000000000
Stock-based compensation2621581009210996133
Balance sheet at fiscal year end
Cash and short-term investments92436546607788428376681588
Debt incl. finance leases—5495964324314464372,007
Total assets—4656327041,013623546919936
Total liabilities—881565961,8781,8681,8892,3773,013
Shareholders' equity8631540858−870−1,255−1,354−1,468−2,087
Margins and ratios
Gross margin————95.5%95.6%73.7%98.2%95.8%
Operating margin——−656.4%−5,752.0%−827.1%−659.6%−6,528.8%−267.2%−104.2%
Net margin——−711.5%−6,127.9%−841.2%−624.2%−7,021.9%−244.9%−146.0%
Free cash flow margin——−631.7%−4,936.7%−733.2%−546.5%−5,686.6%−235.1%−89.0%
Rule of 40 (growth + FCF margin)———−5,016.4%11.9%−535.1%−5,774.6%2,050.2%37.2%
Return on capital—————————
Return on equity——−79.8%−216.8%—————
Return on assets——−52.6%−75.7%−68.3%−59.2%−111.7%−74.1%−79.0%
Net debt to EBITDA—————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: BridgeBio Pharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with BridgeBio Pharma.